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ABSTRACT: Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is increasingly recognized as a central regulator of multiple
signaling pathways in inflammation and cancer, and the ability to use chemical biological tools to investigate its biological effects
is very attractive. A peptide comprising a TAT-conjugated Nrf2 sequence is shown to activate Nrf2 and its downstream target
gene heme-oxygenase-1 (HO-1) in a dose-dependent manner in intact human THP-1 monocytes. Levels of Nrf2 protein peak
after 3 h, whereas HO-1 mRNA and protein peak after 6 and 12 h, respectively. The peptide is also shown to inhibit the
production of the pro-inflammatory cytokine TNF. The TAT-14mer constitutes a useful chemical biology tool with potential
therapeutic applications.
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N
uclear factor (erythroid-derived 2)-like 2 (Nrf2) is a
transcription factor and member of the Cap'N'collar
family of proteins.
1 Nrf2 plays a central role in the response to
various types of stress by activating a myriad of cellular
antioxidants,
2 detoxification enzymes,
3 drug efflux pumps,
4 and
other cytoprotective proteins.
5 As such, it is closely controlled
in most cells by the presence of a protein called Kelch-like
ECH-associated protein 1 (Keap1).
6 Keap1 binds to Nrf2 and
induces ubiquitination and proteasome-mediated degradation,
thus maintaining low levels of the protein under normal
conditions. In response to oxidative stimuli, the Nrf2-Keap1
interaction is perturbed, and Nrf2 translocates into the nucleus
where it forms a dimer with small Maf proteins
7 and binds to
the antioxidant response element (ARE) in the regulatory
regions of its target genes (Figure 1A). This results in the
production of proteins that have a protective effect for the cell.
These include the cellular antioxidants heme-oxygenase 1 (HO-
1),
8 proteins that regulate glutathione biosynthesis,
9 and the
phase II enzyme NAD(P)H:quinone oxidoreductase 1
(NQO1).
10
Recently, Nrf2 has been recognized as an important regulator
of inflammation. Nrf2 knockout mice are more susceptible to
inflammation than wild-type mice, and Nrf2 exerts anti-
inflammatory effects in cells in vitro.
11 This makes Nrf2 an
interesting target for the development of compounds with
potential anti-inflammatory activity. To date, most effort has
focused on either the triterpenoid compounds CDDO-Im and
CDDO-Me or on covalent inhibitors that bind to cysteines on
the surface of Keap1 that have been suggested to be important
for the protein−protein interactions. CDDO-Im and CDDO-
Me are synthetic analogues of a triterpene and have been
shown to activate the Nrf2 pathway and induce high levels of
antioxidant enzymes.
12 Both have protective effects in animal
models of inflammation, with CDDO-Im demonstrating
protection in an animal model of sepsis (a blood-borne
infection causing acute inflammation and affecting several
tissues). In addition, CDDO-Me is currently in phase III clinical
trials in type II diabetics with chronic kidney disease.
13 More
recently, Gray and co-workers described the identification of a
small molecule that inhibited the Nrf2/Keap1 interaction
through covalent modification of Cys151 of the human Keap1
and led to activation of Nrf2.
14 The authors built a structure−
activity relationship for the relatively simple compound AI-1
that acts as a good lead for further development. However,
covalent modification may be less desirable in a drug due to off-
target effects in vivo. Electrophiles that interact with the
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AI-1, may well interact with the cysteines or other nucleophiles
on other proteins and may also be substrates for the reaction
with, for example, high levels of glutathione.
These observations suggest that an approach involving
simpler compounds than CDDO-Me that interact to block
Nrf2/Keap1 through noncovalent interactions are desirable and
have great therapeutic potential. Hannink and co-workers have
shown that short peptides based upon the Nrf2 binding region
to the Kelch domain of Keap1 can bind with high affinity where
the central DEETGE site is maintained.
15 Three peptides of 10,
14, and 16 amino acid length were designed, and the 16mer and
14mer showed high affinity binding, while the 10mer also
bound but with lower affinity. The structure of the 16mer
peptide bound to the Kelch domain is shown in Figure 1B.
While peptides are not ideal drug candidates, they are very
useful as chemical tools, particulary when conjugated to a cell-
penetrating peptide (CPP) such as the trans-activating
transcriptional activator (TAT) peptide derived from HIV.
16
A peptide targeted at the protein−protein interaction between
the PSD95 and the NR2B subunit of the NMDA receptor has
proved to be an effective intracellular regulator of the
interaction, useful in stroke.
17 Although it has been suggested
that TAT-peptides targeting Nrf2/Keap1 do not function
18 and
more recently that even shorter peptides can be used to target
the interaction,
19 we focused on the conjugation of TAT to the
Hannink peptides, for which there is structural data for binding.
Using standard Fmoc chemistry and automated synthesis, we
generated three peptides with the TAT sequence located at the
amine terminus of the 10-, 14-, and 16mer peptides (TAT-10,
TAT-14, and TAT-16, Figure 1C). The peptides were purified
by HPLC to >90% pure and were then screened for their ability
to activate HO-1 gene expression in intact THP-1 cells (a
human monocytic cell line), previously validated as a model for
the study of the Nrf2 pathway in human monocytes.
20 HO-1 is
a downstream product of the activation of Nrf2. Only the TAT-
14 peptide was seen to activate HO-1 expression, suggesting
that the conjugation of the TAT peptide to the 10- and 16mer
peptide was either not enhancing uptake into cells or was
inhibiting the binding of the peptides to the Kelch domain
(Figure 2A). Activation by the TAT-14 compound was
significant, however, and this conjugated product was chosen
for further analysis.
Investigation of the effect of the TAT-14 peptide on Nrf2
protein expression was then studied using Western blot
analysis. Cells were incubated with the peptide and a version
of the TAT-14 peptide scrambled in the 14mer region (TAT-
14Sc), which would affect binding to the Kelch domain but the
peptide would still enter the cell (see Figure 1C). Levels of
Nrf2 protein reached a peak after 3 h of incubation with the
TAT-14 peptide and showed no enhancement with the TAT-
14sc peptide (Figure 2B). The TAT-14 peptide had no effect
on Nrf2 mRNA expression, measured by qRT-PCR (data not
shown), suggesting that the increased levels of protein were due
to the interaction of TAT-14 with Keap1 rather than through a
stress-induced increase in basal levels of the transcription factor.
This is also supported by the lack of effect of the scrambled
peptide.
As noted above, the initial screen for the TAT-14 peptide
involved investigation of its effect on expression of HO-1, a
downstream product of the binding of Nrf2 to the ARE. To
clearly define the timing of this effect and also investigate the
effects on HO-1 protein, experiments were carried out using
both qRT-PCR (for mRNA) and Western blotting (for
protein). Effects on HO-1 mRNA by the TAT-14 peptide
were compared with the nonconjugated peptide (14mer) and
also the TAT-14sc peptide. The effects of the TAT-14 peptide
(75 μM) on HO-1 mRNA expression were significant with an
average 24-fold induction at the peak incubation time of 6 h
(Figure 2C). The induction then gradually returned to basal
levels. Neither the 14mer nor the TAT-14sc peptides had any
significant effect on the levels of HO-1 mRNA. HO-1 protein
expression was similarly investigated in comparison with the
TAT-14sc peptide, and this peaked at 12 h, with the TAT-14sc
having no effect (Figure 2D).
The high levels of HO-1 expression allowed the examination
of the dose response of the peptide (Figure 2E). The effect of
the peptide was assessed at 7.5, 18.75, 37.5, and 75 μM and
gave a clear dose response with significant activation also
occurring at the 37.5 μM concentration.
Nrf2 deficiency results in susceptibility to inflammation in
animal models, including bacteria-induced sepsis in mice, and
this is due to an excessive production of pro-inflammatory
cytokines including tumor necrosis factor α (TNF) in the Nrf2
knockout mice. We have previously shown that bacterial
lipopolysaccharide (LPS)-induced TNF production is a valid
cell model of sepsis. Monocytes play a central role in the
inflammatory response during sepsis. Inhibition of Nrf2 using
siRNA leads to the increased production of TNF following
stimulation of THP-1 monocytes by LPS.
20 This suggests that
conversely the release of Nrf2 from Keap1 and its resultant
binding to the ARE may inhibit the production of the cytokine
following a similar stimulation by LPS in these cells. In turn,
this would have an anti-inflammatory effect in this model for
Figure 1. (A) Nrf2 is constitutively expressed but normally binds to
Keap1 and is degraded. Inhibition of Nrf2/Keap1 through interaction
with TAT-14 leads to nuclear translocation and activation of
downstream proteins such as HO-1. (B) Structure of the conserved
DEETGE sequence binding to the Kelch domain and Keap1.
15 (C)
The peptide sequences used in this study.
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stress-free conditions and then treated with TAT-14 or TAT-
14sc for 4 h prior to stimulation with LPS for 3 h. After this, the
cells were lysed and analyzed for TNF mRNA expression by
qRT-PCR (Figure 2F). TAT-14 significantly suppressed LPS-
induced TNF expression, with an average of 61% inhibition of
the cytokine, signifying that the TAT-14 peptide has an anti-
inflammatory effect.
These results demonstrate that the conjugation of a CPP to a
sequence targeting the Nrf2 binding site on Keap1 generates a
chemical biological tool that is able to enter cells and inhibit the
protein−protein interaction, thereby activating Nrf2. Such a
construct also has some biological activity and can act as an
anti-inflammatory. Importantly, this study also demonstrates
that carefully designed “druglike” small molecules that target
the same site on Keap1 could have a similar activity. These
compounds have potential in the treatment of diseases where
resolution of inflammatory processes can play a beneficial role.
The progression of CDDO-Me into the clinic suggests that the
Nrf2/Keap1 interaction is an important target and that
chemical tools such as the TAT-14 peptide will have a role
to play in understanding the biological processes involved in
this pathway, as well as defining a clear therapeutic target.
■ ASSOCIATED CONTENT
* S Supporting Information
Experimental procedures including the peptide synthesis,
purification, and biological evaluation. This material is available
free of charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*Tel: +44-1603-592030. E-mail: m.oconnell@uea.ac.uk
(M.O.). Tel: +44-1603-592026. E-mail: m.searcey@uea.ac.uk
(M.S.).
Author Contributions
The manuscript was written through contributions of all
authors. All authors have given approval to the final version of
the manuscript.
Funding
R.S. is funded through an EPSRC DTA. E.P. was funded by
MRC Grant No. G0801127. J.C. is funded by UEA.
Notes
The authors declare no competing financial interest.
■ ABBREVIATIONS
Nrf2, nuclear factor (erythroid-derived 2)-like 2; Keap1, Kelch-
like ECH-associated protein 1; ARE, antioxidant response
element; TAT, trans-activating transcriptional activator; HO-1,
heme-oxygenase 1; CPP, cell-penetrating peptide; TNF, tumor
necrosis factor
■ REFERENCES
(1) Moi, P.; Chan, K.; Asunis, I; Cao, A.; Kan, Y. W. Isolation of NF-
E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper
transcriptional activator that binds to the tandem NF-E2/AP1 repeat
of the beta-globin locus control region. Proc. Natl. Acad. Sci. U.S.A.
1994, 91, 9926−9930.
Figure 2. (A) Induction of HO-1 by the three TAT peptides. THP-1 cells were treated with the peptide for the time indicated, and levels of HO-1
mRNA were measured using qRT-PCR and normalized to the expression of the housekeeping gene GAPDH (see the Supporting Information for
full experimental details). Means ± SEMs, n =3 ,***p < 0.001. (B) Western blot analysis of the induction of Nrf2 protein following incubation with
the TAT-14 peptide or the TAT-14sc peptide. (C) Induction of HO-1 by the nonconjugated 14mer, the TAT-14sc, and TAT-14. THP-1 cells were
treated with the peptide for the time indicated, and levels of HO-1 mRNA were analyzed using qRT-PCR and normalized to GAPDH expression.
Means ± SEMs, n =3 ,***p < 0.001. (D) Western blot analysis of HO-1 protein levels following treatment with TAT-14 and TAT-14sc.
Representative experiment of n = 3. (E) Dose dependence of HO-1 induction as assessed by qRT-PCR and normalized to GAPDH mRNA
expression. Means ± SEMs, n =3 ,**p < 0.01, ***p < 0.001. (F) TNFα induction following stimulation with LPS in the presence of either TAT-14
or TAT-14Sc. mRNA levels were analyzed using qRT-PCR and normalized to GAPDH. Means ± SEMs, n =3 ,**p < 0.01.
ACS Medicinal Chemistry Letters Letter
dx.doi.org/10.1021/ml300041g | ACS Med. Chem. Lett. 2012, 3, 407−410 409(2) Kobayashi, M.; Yamamoto, M. Molecular mechanisms activating
the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid.
Redox Signaling 2005, 7, 385−394.
(3) Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.;
Oyake, T.; Hayashi, N.; Satoh, K.; Htayama, I.; Yamamoto, Y.;
Nabeshima, Y. An Nrf2/small Maf heterodimer mediates the induction
of phase II detoxifying enzyme genes through antioxidant response
elements. Biochem. Biophys. Res. Commun. 1997, 236, 313−322.
(4) Hayashi, A.; Suzuki, H.; Itoh, M.; Yamamoto, Y.; Sugiyama, Y.
Transcription factor Nrf2 is required for the constitutive and inducible
expression of multidrug resistance-associated protein 1 in mouse
embryo fibroblasts. Biochem. Biophys. Res. Commun. 2003, 310, 824−
829.
(5) Chen, X. L.; Kunsch, C. Induction of cytoprotective genes
through Nrf2/antioxidant response element pathway: A new
therapeutic approach for the treatment of inflammatory diseases.
Curr. Pharm. Des. 2004, 10, 879−891.
(6) Itoh, K.; Wakabayahsi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel,
J. D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant
responsive elements by Nrf2 through binding to the amino-terminal
Neh2 domain. Genes Dev. 1999, 13,7 6 −86.
(7) Itoh, K.; Igarashi, K.; Hayashi, N.; Nishizawa, M.; Yamamoto, M.
Cloning and characterization of a novel erythroid cell-derived CNC
family transcription factor heterodimerizing with the small Maf family
proteins. Mol. Cell. Biol. 1995, 15, 4184−4193.
(8) Alam, J.; Stewart, D.; Touchard, C.; Boinapally, S.; Choi, A. M.;
Cook, J. L. Nrf2, a Cap’n’Collar transcription factor, regulates
induction of the heme oxygenase-1 gene. J. Biol. Chem. 1999, 274,
26071−26078.
(9) Chan, J. Y.; Kwong, M. Impaired expression of glutathione
synthetic enzyme genes in mice with targeted deletion of the Nrf2
basic-leucine zipper protein. Biochim. Biophys. Acta 2000, 1517,1 9 −26.
(10) Venugopal, R.; Jaiswal, A. K. Nrf1 and Nrf2 positively and c-Fos
and Fra1 negatively regulate the human antioxidant response element-
mediated expression of NAD(P)H:quinone oxidoreductase1 gene.
Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14960−14965.
(11) Ma, Q.; Battelli, L.; Hubbs, A. F. Multiorgan autoimmune
inflammation, enhanced lymphoproliferation, and impaired homeo-
stasis of reactive oxygen species in mice lacking the antioxidant-
activated transcription factor Nrf2. Am. J. Pathol. 2006, 168, 1960−
1974.
(12) Thimmulappa, R. K.; Fuchs, R. J.; Malhotra, D.; Scollick, C.;
Traore, K.; Bream, J. H.; Trush, M. A.; Liby, K. T.; Spron, M. B.;
Kensler, T. W.; Biswal, S. Preclinical evaluation of targeting the Nrf2
pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection
from LPS-induced inflammatory response and reactive oxygen species
in human peripheral blood mononuclear cells and neutrophils.
Antioxid. Redox Signaling 2007, 9, 1963−1970.
(13) Pergola, P. E.; Raskin, P.; Toto, R. D.; Meyer, C. J.; Huff, J. W.;
Grossman, E. B.; Krauth, M.; Ruiz, S.; Audhya, P.; Christ-Schmidt, H.;
Wittes, J.; Warnock, D. G. Bardoxolone methyl and kidney function in
CKD with type 2 diabetes. N. Engl. J. Med. 2011, 365, 327−336.
(14) Hur, W.; Sun, Z.; Jiang, T.; Mason, D. E.; Peters, E. C.; Zhang,
D. D.; Luesch, H.; Schultz, P. G.; Gray, N. S. A small-molecule inducer
of the antioxidant response element. Chem. Biol. 2010, 17, 537−547.
(15) Lo, S. C.; Li, X.; Henzl, M. T.; Beamer, L. J.; Hannink, M.
Structure of the Keap1:Nrf2 interface provides mechanistic insight into
Nrf2 signaling. EMBO J. 2006, 3605−3617.
(16) Deshayes, S.; Morris, M. C.; Divita, G.; Heitz, F. Cell-
penetrating peptides: tools for intracellular delivery of therapeutics.
Cell. Mol. Life Sci. 2005, 62, 1839−1849.
(17) Schwarze, S. R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S. F. In vivo
protein transduction: Delivery of a biologically active protein into the
mouse. Science 1999, 285, 1569−1572.
(18) Zhao, J.; Redell, J. B.; Moore, A. N.; Dash, P. K. A novel strategy
to activate cytoprotective genes in the injured brain. Biochem. Biophys.
Res. Commun. 2011, 407, 501−506.
(19) Hancock, R.; Bertrand, H. C.; Tsujita, T.; Naz, S.; El-Bakry, A.;
Laoruchupong, J; Hayes, J. D.; Wells, G. Peptide inhibitors of the
Keap1-Nrf2 protein-protein interaction. Free Radical Biol. Med. 2012,
52, 444−451.
( 2 0 )R u s h w o r t h ,S .A . ;M a c E w a n ,D .J . ;O ' C o n n e l l ,M .A .
Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidor-
eductase 1 and heme oxygenase-1 protects against excessive
inflammatory responses in human monocytes. J. Immunol. 2008,
181, 6730−6737.
ACS Medicinal Chemistry Letters Letter
dx.doi.org/10.1021/ml300041g | ACS Med. Chem. Lett. 2012, 3, 407−410 410